Is Nuvalent, Inc. (NUVL) a Buy, Sell, or Hold?
Nuvalent, Inc.
NASDAQ:NUVL
$123.96 USD
$0.02 (0.02%)
- Volume
- 3.09M
- Average Volume
- 2.26M
- Market Capitalization
- $9.12B
- P/E Ratio
- -20.46
- Dividend Yield
- 0.00%
- Price Target
- $124.00
- Year High
- $123.99
- Year Low
- $71.13
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $16.14
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | James R. Porter |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | NUVL |
| CUSIP | 670703107 |
| CIK | 0001861560 |
| Web | https://www.nuvalent.com |
| Phone | 857 357 7000 |
| Currency | USD |
| Employees | 234 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.00 |
| Payout Ratio | 0.00 |
| Current Ratio | 16.14 |
| Quick Ratio | 16.14 |
| Cash Ratio | 1.97 |
Sales & Book Value
| Annual Sales | $- |
| Price / Sales | 0.00 |
| Cash Flow | -3.98 |
| Price / Cash Flow | -29.15 |
| Price / Book | 8.30 |
Price Target and Rating
| Average Stock Price Forecast | $124.00 |
| High Stock Price Forecast | $165.00 |
| Low Stock Price Forecast | $122.85 |
| Forecast Upside/Downside | -0.03% |
| Consensus Rating | Strong Sell |
| Rating Score(0-5) | 1 |
| Research Coverage | 19 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-5.85 |
| Trailing P/E Ratio | -20.46 |
| PEG Ratio | 0.69 |
| P/E Growth | 0.69 |
| Net Income | $-425.38M |
| Net Margin | 0.00% |
| Pretax Margin | 0.00% |
| Return on Equity | -42.78% |
| Return on Assets | -33.81% |
Financials Score
| AltmanZ Score | 33.78 |
| Piotroski Score | 2.00 |
| Working Capital | 1.23B |
| Total Assets | 1.33B |
| Ebit | -436.61M |
| Market Cap | 9.12B |
| Total Liabilities | 156.78M |
Poll Results
About Nuvalent, Inc. (NASDAQ:NUVL) Stock
Nuvalent, Inc. is a clinical-stage biopharmaceutical firm dedicated to pioneering novel therapeutic solutions for individuals battling cancer. The company's pipeline features two prominent drug candidates. One of these is NVL-520, a highly selective ROS1 inhibitor capable of penetrating the brain. This compound is specifically designed to target ROS1 fusions that possess the normal ROS1 kinase domain, and crucially, it retains activity against mutations known to confer resistance to both approved and experimental ROS1 inhibitors. NVL-520 is currently undergoing Phase I clinical evaluation. Nuvalent's second key asset is NVL-655, an ALK-selective inhibitor that also exhibits brain-penetrant properties. This therapy seeks to address significant limitations of earlier generations of ALK inhib ... itors (first-, second-, and third-generation), including the development of treatment resistance, central nervous system-related adverse effects, and brain metastases. NVL-655 is presently being assessed in Phase I/II clinical trials. The company was established in 2017 and is based in Cambridge, Massachusetts.
2026-07-13 14:00:00
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of [url="]Kahn Swick and Foti[/url], LLC (âKSFâ) are investigating the propo
2026-07-13 13:29:00
NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Nuvalent, Inc. (NasdaqGS: NUVL) to GSK plc (NYSE: GSK). Under the terms of the proposed transaction, shareholders of Nuvalent will receive $124.00 in cash for each share of Nuvalent that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate.
2026-07-02 05:08:00
MILWAUKEE, July 02, 2026 (GLOBE NEWSWIRE) -- Ademi LLP is investigating Nuvalent (NASDAQ: NUVL) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with GSK plc.
2026-06-30 13:16:00
BALA CYNWYD, Pa., June 30, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ([email protected]) or Marc Ackerman ([email protected]) at 855-576-4847. There is no cost or financial obligation to you.
Are NUVL, CPRX, TMHC Obtaining Fair Deals for their Shareholders?
2026-06-25 13:00:00
Are NUVL, CPRX, TMHC Obtaining Fair Deals for their Shareholders? PR Newswire NEW YORK, June 25, 2026
2026-06-24 08:15:12
Pre-Market Stock Futures: Futures are trading higher this morning, but if you've ever heard the old saying, "when the chips are down", that was the poster child phrase for Tuesday's session, as technology stocks, and specifically the semiconductor stocks, followed a worldwide sell-off that initially began in Korea and carried around the globe. When... Here Are Wednesday's Best Wall Street Analyst Research Calls: Devon Energy, Flowserve, Klaviyo, Macerich, Merck, Nucor, Take-Two Interactive Software, Twilio, and More
2026-06-16 09:20:00
MONSEY, N.Y., June 16, 2026 (GLOBE NEWSWIRE) -- The law firm of Wohl & Fruchter LLP is investigating the fairness of the proposed sale of Nuvalent, Inc. (Nasdaq: NUVL) (“NUVL”) for $124.00 per share in cash to GSK in a tender offer.
Are AVNS, NUVL, XOMA, TBRG Obtaining Fair Deals for their Shareholders?
2026-06-12 11:47:00
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws
Frequently Asked Questions
-
What is the current Nuvalent, Inc. (NUVL) stock price?
-
Nuvalent, Inc.(NASDAQ:NUVL) stock price is $123.96 in the last trading session. During the trading session, NUVL stock reached the peak price of $123.99 while $71.13 was the lowest point it dropped to. The percentage change in NUVL stock occurred in the recent session was 0.02% while the dollar amount for the price change in NUVL stock was $0.02.
-
NUVL's industry and sector of operation?
-
The NASDAQ listed NUVL is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of NUVL?
-
Deborah Ann Miller | Chief Legal Officer & Secretary
Henry Pelish | Chief Scientific Officer
Chelcie Lister | Senior Director of Investor Relations & Corporate Communications
Benjamin Lane | Chief Technical Operations Officer
James R. Porter | Chief Executive Officer, President & Director -
How many employees does NUVL have?
-
Number of NUVL employees currently stands at 234. NUVL operates from One Broadway, Cambridge, MA 02142, US.
-
Link for NUVL official website?
-
Official Website of NUVL is: https://www.nuvalent.com
-
How do I contact NUVL?
-
NUVL could be contacted at phone #857 357 7000 and can also be accessed through its website. NUVL operates from One Broadway, Cambridge, MA 02142, US.
-
How many shares of NUVL are traded daily?
-
The average number of NUVL shares traded daily for last 3 months was 2.26M.
-
What is the market cap of NUVL currently?
-
The market value of NUVL currently stands at $9.12B with its latest stock price at $123.96